These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11766619)

  • 21. Irbesartan: a review of its use in hypertension and diabetic nephropathy.
    Croom KF; Plosker GL
    Drugs; 2008; 68(11):1543-69. PubMed ID: 18627212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
    Sasso FC; Carbonara O; Persico M; Iafusco D; Salvatore T; D'Ambrosio R; Torella R; Cozzolino D
    Diabetes Care; 2002 Nov; 25(11):1909-13. PubMed ID: 12401731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 25. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 26. What is the impact of PRIME on real-life diabetic nephropathy?
    Ruilope LM
    Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
    Ruggenenti P; Remuzzi G
    Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 29. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
    Rodby RA; Chiou CF; Borenstein J; Smitten A; Sengupta N; Palmer AJ; Roze S; Annemans L; Simon TA; Chen RS; Lewis EJ;
    Clin Ther; 2003 Jul; 25(7):2102-19. PubMed ID: 12946554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 33. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
    J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diabetic nephropathy].
    Haneda M
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():260-9. PubMed ID: 12430239
    [No Abstract]   [Full Text] [Related]  

  • 35. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Evans M; Bain SC; Hogan S; Bilous RW;
    Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 38. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
    MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug companies should not have the final say in the design of clinical trials.
    Kurtzman NA
    Am J Kidney Dis; 2001 Nov; 38(5):1113-4. PubMed ID: 11684568
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.